A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease.

ABSTRACT:

Introduction

Immune checkpoint inhibitors (ICIs) are increasingly used to treat cancers. Kidney immune-related adverse events (IRAEs) are now well recognized, with the incidence of IRAEs ranging from 2% to 5%. Most of the initial data related to kidney IRAEs have focused on acute interstitial nephritis (AIN). There are minimal data on the types and relative frequencies of glomerular diseases associated with ICIs, their treatment, and outcomes.

Methods

We performed a systematic review and meta-analysis of all biopsy-proven published cases/series of glomerular pathology associated with ICIs. We searched the MEDLINE, EMBASE, and Cochrane databases from inception to February 2020. We abstracted patient-level data, including demographics, cancer and ICI therapy details, and chara

SUBMITTER: Kitchlu A 

PROVIDER: S-EPMC7783581 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature